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Radical prostatectomy, external beam radiotherapy and permanent brachytherapy are the most common treatment options for
nonmetastatic localised adenocarcinoma of the prostate (PCa). Accurate pretherapeutic clinical staging is diﬃcult, the number of
positive cores after biopsy does not imperatively represent the extension of the cancer. Furthermore postoperative upgrading in
Gleason score is frequently observed. Even in a localised setting a certain amount of patients with organ-conﬁned PCa will develop
biochemical progression. In case of a rise in PSA level after radiation the majority of patients will receive androgen deprivation
therapy what must be considered as palliative. If local or systemic progressive disease is associated with evolving neuroendocrine
diﬀerentiation hormonal manipulation is increasingly ineﬀective; radiotherapy and systemic chemotherapy with a platinum agent
and etoposide are recommended. In case of local progression complications such as pelvic pain, gross haematuria, infravesical
obstructionandrectalinvasionwithobstructionandconsecutiveileuscanpossiblyoccur.Inthissituationpalliativeradicalsurgery
is a therapy option especially in the absence of distant metastases. A case with local and later systemic progression after permanent
brachytherapy is presented here.
1.CaseReport
A 65-year-old patient wasreferred to our urological clinic for
a prostate biopsy indicated for a PSA elevation of 4,5ng/mL.
The patient presented without any previous morbidities in
his medical or urological history and was entirely asymp-
tomatic. Digital rectal examination (DRE) and transrectal
ultrasound (TRUS) of the prostate were normal, the size
of the gland was 36mL. An octant biopsy was conducted
in January 2002 by which adenocarcinoma of the prostate
(PCa) was diagnosed in 1 out of 8 cores. The lesion was cir-
cumscribed with a length below 2mm and a Gleason grade
of 2, WHO grade was 1, all the other seven biopsies were
classiﬁedasbenignprostatichyperplasiaandchronicinﬂam-
mation. Following discussion of all therapeutical options,
the patient decided to undergo permanent brachytherapy
with J125. 62 seeds with 0,467mCi/seed were implanted, total
activitywas28,95mCi,andpostoperativecoursewaswithout
any complications.
Duringtheearlypostoperativephase,thepatientwasfree
of complaints, there was neither a sign of incontinence nor
any stool disorder, even the erectile function was assessed by
an IIEF-score of 21. PSA was constantly decreasing to reach
its nadir of 0,75ng/mL 15 months after seed implantation.
21 months after brachytherapy, the ﬁrst increase of PSA
up to 2,6 was observed. Presuming the possibility of a so-
called “PSA bouncing” with an episode of prostatitis a cycle
of antibiotic therapy with ciproﬂoxacin over three weeks was
administered, after which PSA fell again to a level of 2,11. At
the subsequent follow-up examination half a year later, the
patient presented with obvious local and systemic progres-
sion: PSA rose up to 8,1ng/mL with a doubling time of three
months, and digital rectal examination showed a dense left
lobe with a ﬁrm node on the contralateral side. At this time,
the patient refused restaging and rejected the recommended
LHRH agonist therapy. After prophylactic radiation to the
breasts with a dose of 1500cGy antiandrogen monotherapy
with bicalutamide 150mg per day was initiated. Receiving2 Advances in Urology
this medication a drop of PSA to 2,4ng/mL was achieved,
the patient was furthermore feeling asymptomatic.
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of antiandrogen treatment, reevaluation was conducted.
While choline PET-CT showed an increased ﬂuorocholine
(FCH) metabolism in the right lobe of the prostate with
no signs of lymph node or bone metastases, a rebiopsy of
the gland yielded a dramatic upstaging and upgrading of
the local disease: of 15 cores taken 13 were inﬁltrated by
prostate cancer with Gleason Score 8 (4 + 4), WHO grade
was 3. Antiandrogen therapy was stopped; the LHRH agonist
leuprorelin acetate was administered. Due to the history of
brachytherapy, any form of further external beam radiation
was not feasible.
Only two months later, the patient had to be hospitalised
again because of gross haematuria and clot retention. A CT
scan showed local progression with a large solid tumour dor-
sal of the right side of the prostate and bladder with a diam-
eter of 6cm as well as pathologically enlarged lymph nodes
in the pelvis up to 2cm. Due to continuous bleeding under
bladder irrigation palliative transurethral resection of the
prostate had to be performed, 15g of fragile tumour tissue
were removed. The pathological report conﬁrmed the diag-
nosis of an adenocarcinoma with a Gleason score of 8, but
additionally larger areas with neuroendocrine diﬀerentiation
were found.
After a period of the next three weeks, transurethral
reintervention for severe haematuria had to be undertaken,
and due to persistent bleeding transfusions of several red
cell concentrates were necessary. Obstruction of the upper
urinary tract led to bilateral nephrostomies. After discharge,
several recurrent episodes of bleeding and clot retention
occurred. The general health status deteriorated preventing
the initiation of systemic chemotherapy.
Only two months following the previous CT scan, MRI
showed a large solid local tumour with a diameter of now
9cm inﬁltrating the trigone and the bladder ﬂoor on each
side (Figure 1). Beneath lymph nodes, up to 3cm dissemi-
nated bone metastases were diagnosed. Four years after the
“ﬁrst deﬁnitive” therapy, the patient received a palliative
ileal conduit to control local symptoms. With regards to the
limited life expectancy, the prostate and bladder remained
in situ; recurrent bleeding was controlled by percutaneous
transluminal angiography and coil embolization; addition-
ally, instillations with formalin were performed twice. The
patient’s health status was declining rapidly and three weeks
after the last surgery, he died due to dilatation of the right
ventricle and pulmonary oedema. Beyond that, autopsy
showed extensive pulmonary metastases.
2. Discussion
Accurate staging of prostate cancer on the basis of clinical
features such as PSA, DRE, and histology of biopsy is
diﬃcult. The number of positive cores does not imperatively
represent the extension of the cancer, furthermore, in about
50% an upgrading in Gleason score has to be observed
after performing radical prostatectomy. Besides, radical
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Figure 1: MRI demonstrating a local solid tumour with a diameter
of 9cm inﬁltrating the trigone and the bladder ﬂoor on each side.
prostatectomy and external beam radiotherapy, permanent
brachytherapy is one treatment option of nonmetastatic-
localised PCa [1]. Even in a localised setting, 10–20% of
patients with organ-conﬁned PCa will develop biochemical
progression within 5–10 years; if the cancer is locally
advanced at the time of treatment, the progression rate
increases to up to 30–50% [2–4]. 70% of the patients
with PSA relapse after brachytherapy, present with local
persistence as the only site of recurrence, depending on the
initial tumour stage [2, 5]. In case of a rise in PSA level
after radiation therapy the majority of patients will receive
androgen deprivation therapy. Since this must be considered
as palliative, a reverse strategy is salvage radical prostate-
ctomy (SRP). Heidenreich et al. reported a retrospective
series of 55 men with biopsy-proven, locally recurrent PCa
after primary radiotherapy. Predictors of organ-conﬁned
PCa with negative surgical margins were biopsy Gleason
score prior to salvage radical prostatectomy, <50% positive
biopsy cores, PSA doubling-time >12 months, and low-dose
brachytherapy. SRP was judged as a surgically challenging
but eﬀective secondary local treatment with curative intent
[2]. Furthermore, studies about cryotherapy, brachytherapy
and high-intensity focused ultrasound (HIFU) with partly
encouraging results but smaller numbers of patients were
published [6].Advances in Urology 3
If SRP was not performed after PSA relapse castration
resistant PCa with local progression and associated com-
plications such as pelvic pain, gross haematuria, infravesi-
cal obstruction, and rectal invasion with obstruction and
consecutive ileus can possibly occur in the further course;
each of those sequels impairs the patient’s well-being sig-
niﬁcantly. Voiding problems may require lifelong indwelling
catheters, obstruction of the ureters often results in long-
term placement of nephrostomy tubes or ureteral stents,
and despite those measurements renal failure may occur. In
this situation, palliative radical surgery is a therapy option
especially in the absence of distant metastases.
Leibovici et al. were looking at the eﬀect of cystoprosta-
tectomy for palliation of symptomatic bladder invasion by
prostate cancer. 21 patients had previous local therapy, 17
were primary T4 tumours. During surgery, rectal injuries
occurred in 13%, there were no perioperative deaths. In 79%
(30/38 patients), local symptoms were relieved permanently
after the operation. 3 patients (8%) suﬀered from persistent
pelvic pain, another 3 patients from urinary incontinence,
and 1 from on going haematuria. The average interval
betweensurgeryandclinicalsystemicdiseasewas26months,
median disease speciﬁc survival was 31 months [7]. Pﬁster
et al. published a series of 20 patients with locally ad-
vanced prostate cancer. 70% had an indwelling catheter
due to infravesical obstruction, 10% had nephrostomy tubes
inserted, 30% recurrent gross haematuria with the need for
blood transfusions, 25% suﬀered from rectal obstruction
with consecutive subileus. 15 patients received cystoprosta-
tectomy, median operation time was 260min, blood loss was
500mL. In 80%, durable symptom reduction was achieved,
median symptom-free survival added up to 15,3 (6–25)
months, median survival up to 20,4 (9–28) months [8].
Neuroendocrine diﬀerentiation. The number of neu-
roendocrine cells increases after puberty until an optimum
levelthatpersistsbetweentheageof25and54,theyrepresent
the third epithelial cell type on normal prostatic tissue in
addition to basal and secretory cells. Because of the lack of
androgen receptors on these cells in normal and neoplastic
prostates, they are androgen-insensitive, so hormonal ther-
apy is not a true option for neuroendocrine prostate cancer
[9]. In case of loco-regional disease, surgical resection with
or without adjuvant treatment (chemotherapy, radiation) is
recommended [10]. For prostate cancer with a Gleason score
between 8 and 10, Krauss et al. reported inferior clinical
outcomes for patients treated with primary radiotherapy if
neuroendocrine diﬀerentiation exceeds >1%, 10-year distant
metastases rates and cause speciﬁc survival were signiﬁcantly
lower. In this paper no diﬀerences in outcomes were seen for
patients with 0% versus <1% neuroendocrine diﬀerentiation
[11].
For patients with metastatic-stage disease, systemic
chemotherapy with a platinum agent (cisplatin or carbo-
platin) and etoposide is recommended. However, due to
aggressive histological features of neuroendocrine carcino-
mas response durations are often short [10]. In a study
published by Culine et al., 41 patients were treated with
a combination of docetaxel and cisplatin. PSA response
rate was 48% and clinical beneﬁt was observed in 45% of
patients, median survival was 12 months [12]. Stein et al.
published a cohort of 30 patients treated with cisplatin-
based chemotherapy with or without pelvic radiotherapy.
After an initial response, 25 patients succumbed to massive
local and/or distant failure [13]. Based on the disappoint-
ing results with the established therapy strategies, novel
approaches have to be implicated. Somatostatin analogues,
serotonin and bombesin antagonists, and cytokines are
under investigation [14]. Recently, Sciarra et al. reported a
median overall survival superior to the 10-month median
survival in patients with hormone refractory disease using a
combination of estrogens and somatostatin [15].
Thecasepresentedheremayhaveproﬁtedfromasurgical
approach once rapid progression had become obvious.
It teaches that palliative radical tumour surgery should
be considered in patients with locally advanced disease,
especially when symptoms impair the patient’s well being.
Even in cases with widespread metastases, an eﬀective local
symptom control can be achieved for the last months of their
lives.
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